1. Abstract
To address the current threat of antimalarial resistance, countries need innovative solutions for timely and informed decision-making. Integrating molecular resistance marker surveillance into routine malaria surveillance in pre-elimination contexts offers a potential early warning mechanism to identify resistance signals and target areas for further investigation, including therapeutic efficacy studies. However, there is limited evidence on what influences the performance of such a system in resource-limited settings.
From March 2018 to February 2020, a sequential mixed-methods study was conducted in primary healthcare facilities in a South African pre-elimination setting to explore factors influencing the flow, quality and linkage of malaria case notification and antimalarial molecular resistance marker data. Using a process-oriented framework, we undertook monthly and quarterly data linkage and consistency analysis at different levels of the health system, as well as a survey, focus group discussions and interviews to identify potential barriers to, and enhancers of, the roll-out and uptake of this integrated information system.
Over two years, 4,787 confirmed malaria cases were notified from 42 primary healthcare facilities in the Nkomazi sub-district, Mpumalanga, South Africa. Of the notified cases, 78.5% (n=3,758) were investigated, and 55.1% (n=2,636) were successfully linked to their Plasmodium falciparum molecular resistance marker profiles. Five tangible processes—malaria case detection and notification, sample collection, case investigation, analysis and reporting—were identified within the process-oriented logic model. Workload, training, ease of use, supervision, leadership, and resources were recognized as cross-cutting influencers affecting the program’s performance.
Approaching malaria elimination, linking molecular markers of antimalarial resistance to routine malaria surveillance is feasible. However, cross-cutting barriers inherent in the healthcare system can determine its success in a resource-limited setting.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Human Research Ethics Committee of the Faculty of Health Sciences at the University of Cape Town (HREC REF Number: 698/2019 and 038/2020 (Document, S1 and S2), including for data obtained in the SS4ME study (HREC REF Number: 519/2017 [Document S3]). SS4ME was also endorsed by the South African Department of Health, the National Institute for Communicable Diseases (NICD) and the Mpumalanga Malaria Programme. All partners were notified, and their staff were informed of the study, including NMP staff, information officers, clinicians and data clerks. Verbal and written consent were obtained from participants using Tools S2 (b) and (c) in the supporting information.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All qualitative relevant data are within the manuscript and its Supporting Information files. The quantitative datasets generated and/or analysed during the study are available at the WWARN Tracking Resistance website (https://www.wwarn.org/tracking-resistance/artemisinin-molecular-surveyor).
https://www.wwarn.org/tracking-resistance/artemisinin-molecular-surveyor
